In the pharmaceutical industry, tablets remain the most commonly produced oral dosage form; as such, granulation, which allows primary powder particles to adhere and form granules, is one of the most important unit operations in drug manufacturing.
A number of different granulation and compression technologies are available to pharmaceutical manufacturers, all of which have individual strengths and weaknesses depending on the specific application; however, the theory of granulation is often poorly understood and the selection of a particular machine and granulation method is frequently done on the basis of tradition and the operator’s own experience, rather than by using strict scientific or cost-benefit criteria.
The basic techniques have changed dramatically in recent years and granulation for controlled release, extrusion, spheronization, fluidization techniques, spray drying, melt extrusion, oral dispersion technology and roller compaction are all new technologies that are increasingly being used in modern pharmaceutical production and offer many advantages compared with previously available processes.
In essence, a granulator is a multipurpose processor that’s equally suitable for the high-speed dispersion of dry powders, aqueous or solvent granulations, effervescent products, wet and melt pelletization. At GEA, we supply a complete range of granulation process equipment. With the company’s history of expertise in the market, our reliable legacy of supply, support and manufacturing excellence, you can rest assured that every pharmaceutical plant and system from GEA is a unique union of proven technology and individual solutions.
Offering a wide selection of equipment, modules and systems, our experts are available to provide objective, unbiased advice on the merits and implications of each process and deliver the best solution for your specific granulation application.
GEA’s first contained manufacturing line, including integrated granulation and tablet compression for the production of steroid/hormonal drugs, at STELLAPHARM in Vietnam is approaching completion
Discover GEA's groundbreaking partnership with Oncogen Pharma in Malaysia, as they secure a multi-million Euro contract for the production of oral solid dosage (OSD) forms to treat cancer. Learn how GEA's end-to-end solutions and innovative technologies overcame challenges during the COVID-19 pandemic, ensuring successful project completion and customer satisfaction.
Будьте в курсе инноваций и историй GEA, подписавшись на новостную рассылку от GEA.Подписаться
Мы всегда готовы помочь! Пожалуйста, сообщите некоторые данные и мы предоставим ответ на Ваш запрос.Свяжитесь с нами